ChloroquineV1, Pmc, Corpus, bibRecord, 000263

Repurposing Quinacrine against Ebola Virus Infection In Vivo

Identifieur interne : 000263 ( Pmc/Corpus ); précédent : 000262; suivant : 000264

Repurposing Quinacrine against Ebola Virus Infection In Vivo

Auteurs : Thomas R. Lane ; Jason E. Comer ; Alexander N. Freiberg ; Peter B. Madrid ; Sean Ekins

Source :

Antimicrobial Agents and Chemotherapy [ 0066-4804 ] ; 2019.

RBID : PMC:6709481

Abstract

Quinacrine hydrochloride is a small-molecule, orally bioavailable drug that has been used clinically as an antimalarial and for many other applications. A machine learning model trained on Ebola virus (EBOV) screening data identified quinacrine as a potent (nanomolar) in vitro inhibitor.

Url:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709481

DOI: 10.1128/AAC.01142-19
PubMed: 31307979
PubMed Central: 6709481

Links to Exploration step

PMC:6709481

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Repurposing Quinacrine against Ebola Virus Infection <italic>In Vivo</italic>
</title>
<author><name sortKey="Lane, Thomas R" sort="Lane, Thomas R" uniqKey="Lane T" first="Thomas R." last="Lane">Thomas R. Lane</name>
<affiliation><nlm:aff id="aff1"><addr-line>Collaborations Pharmaceuticals, Inc., Raleigh, North Carolina, USA</addr-line>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Comer, Jason E" sort="Comer, Jason E" uniqKey="Comer J" first="Jason E." last="Comer">Jason E. Comer</name>
<affiliation><nlm:aff id="aff2"><addr-line>Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA</addr-line>
</nlm:aff>
</affiliation>
<affiliation><nlm:aff id="aff3"><addr-line>Institutional Office of Regulated Nonclinical Studies, University of Texas Medical Branch, Galveston, Texas, USA</addr-line>
</nlm:aff>
</affiliation>
<affiliation><nlm:aff id="aff4"><addr-line>Department of Pathology, University of Texas Medical Branch, Galveston, Texas, USA</addr-line>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Freiberg, Alexander N" sort="Freiberg, Alexander N" uniqKey="Freiberg A" first="Alexander N." last="Freiberg">Alexander N. Freiberg</name>
<affiliation><nlm:aff id="aff4"><addr-line>Department of Pathology, University of Texas Medical Branch, Galveston, Texas, USA</addr-line>
</nlm:aff>
</affiliation>
<affiliation><nlm:aff id="aff5"><addr-line>Sealy Institute for Vaccine Sciences, University of Texas Medical Branch, Galveston, Texas, USA</addr-line>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Madrid, Peter B" sort="Madrid, Peter B" uniqKey="Madrid P" first="Peter B." last="Madrid">Peter B. Madrid</name>
<affiliation><nlm:aff id="aff6"><addr-line>Bioscience Division, SRI International, Menlo Park, California, USA</addr-line>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Ekins, Sean" sort="Ekins, Sean" uniqKey="Ekins S" first="Sean" last="Ekins">Sean Ekins</name>
<affiliation><nlm:aff id="aff1"><addr-line>Collaborations Pharmaceuticals, Inc., Raleigh, North Carolina, USA</addr-line>
</nlm:aff>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">31307979</idno>
<idno type="pmc">6709481</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709481</idno>
<idno type="RBID">PMC:6709481</idno>
<idno type="doi">10.1128/AAC.01142-19</idno>
<date when="2019">2019</date>
<idno type="wicri:Area/Pmc/Corpus">000263</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000263</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Repurposing Quinacrine against Ebola Virus Infection <italic>In Vivo</italic>
</title>
<author><name sortKey="Lane, Thomas R" sort="Lane, Thomas R" uniqKey="Lane T" first="Thomas R." last="Lane">Thomas R. Lane</name>
<affiliation><nlm:aff id="aff1"><addr-line>Collaborations Pharmaceuticals, Inc., Raleigh, North Carolina, USA</addr-line>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Comer, Jason E" sort="Comer, Jason E" uniqKey="Comer J" first="Jason E." last="Comer">Jason E. Comer</name>
<affiliation><nlm:aff id="aff2"><addr-line>Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA</addr-line>
</nlm:aff>
</affiliation>
<affiliation><nlm:aff id="aff3"><addr-line>Institutional Office of Regulated Nonclinical Studies, University of Texas Medical Branch, Galveston, Texas, USA</addr-line>
</nlm:aff>
</affiliation>
<affiliation><nlm:aff id="aff4"><addr-line>Department of Pathology, University of Texas Medical Branch, Galveston, Texas, USA</addr-line>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Freiberg, Alexander N" sort="Freiberg, Alexander N" uniqKey="Freiberg A" first="Alexander N." last="Freiberg">Alexander N. Freiberg</name>
<affiliation><nlm:aff id="aff4"><addr-line>Department of Pathology, University of Texas Medical Branch, Galveston, Texas, USA</addr-line>
</nlm:aff>
</affiliation>
<affiliation><nlm:aff id="aff5"><addr-line>Sealy Institute for Vaccine Sciences, University of Texas Medical Branch, Galveston, Texas, USA</addr-line>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Madrid, Peter B" sort="Madrid, Peter B" uniqKey="Madrid P" first="Peter B." last="Madrid">Peter B. Madrid</name>
<affiliation><nlm:aff id="aff6"><addr-line>Bioscience Division, SRI International, Menlo Park, California, USA</addr-line>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Ekins, Sean" sort="Ekins, Sean" uniqKey="Ekins S" first="Sean" last="Ekins">Sean Ekins</name>
<affiliation><nlm:aff id="aff1"><addr-line>Collaborations Pharmaceuticals, Inc., Raleigh, North Carolina, USA</addr-line>
</nlm:aff>
</affiliation>
</author>
</analytic>
<series><title level="j">Antimicrobial Agents and Chemotherapy</title>
<idno type="ISSN">0066-4804</idno>
<idno type="eISSN">1098-6596</idno>
<imprint><date when="2019">2019</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p>Quinacrine hydrochloride is a small-molecule, orally bioavailable drug that has been used clinically as an antimalarial and for many other applications. A machine learning model trained on Ebola virus (EBOV) screening data identified quinacrine as a potent (nanomolar) <italic>in vitro</italic>
 inhibitor.</p>
</div>
</front>
</TEI>
<pmc article-type="brief-report"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
  <front><journal-meta><journal-id journal-id-type="nlm-ta">Antimicrob Agents Chemother</journal-id>
<journal-id journal-id-type="iso-abbrev">Antimicrob. Agents Chemother</journal-id>
<journal-id journal-id-type="hwp">aac</journal-id>
<journal-id journal-id-type="pmc">aac</journal-id>
<journal-id journal-id-type="publisher-id">AAC</journal-id>
<journal-title-group><journal-title>Antimicrobial Agents and Chemotherapy</journal-title>
</journal-title-group>
<issn pub-type="ppub">0066-4804</issn>
<issn pub-type="epub">1098-6596</issn>
<publisher><publisher-name>American Society for Microbiology</publisher-name>
<publisher-loc>1752 N St., N.W., Washington, DC</publisher-loc>
</publisher>
</journal-meta>
<article-meta><article-id pub-id-type="pmid">31307979</article-id>
<article-id pub-id-type="pmc">6709481</article-id>
<article-id pub-id-type="publisher-id">01142-19</article-id>
<article-id pub-id-type="doi">10.1128/AAC.01142-19</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Antiviral Agents</subject>
</subj-group>
</article-categories>
<title-group><article-title>Repurposing Quinacrine against Ebola Virus Infection <italic>In Vivo</italic>
</article-title>
<alt-title alt-title-type="running-head">Efficacy of Quinacrine against Ebola Virus</alt-title>
<alt-title alt-title-type="short-authors">Lane et al.</alt-title>
</title-group>
<contrib-group><contrib contrib-type="author"><name><surname>Lane</surname>
<given-names>Thomas R.</given-names>
</name>
<xref ref-type="aff" rid="aff1"><sup>a</sup>
</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Comer</surname>
<given-names>Jason E.</given-names>
</name>
<xref ref-type="aff" rid="aff2"><sup>b</sup>
</xref>
<xref ref-type="aff" rid="aff3"><sup>c</sup>
</xref>
<xref ref-type="aff" rid="aff4"><sup>d</sup>
</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Freiberg</surname>
<given-names>Alexander N.</given-names>
</name>
<xref ref-type="aff" rid="aff4"><sup>d</sup>
</xref>
<xref ref-type="aff" rid="aff5"><sup>e</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes"><name><surname>Madrid</surname>
<given-names>Peter B.</given-names>
</name>
<xref ref-type="aff" rid="aff6"><sup>f</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes"><name><surname>Ekins</surname>
<given-names>Sean</given-names>
</name>
<xref ref-type="aff" rid="aff1"><sup>a</sup>
</xref>
</contrib>
<aff id="aff1"><label>a</label>
<addr-line>Collaborations Pharmaceuticals, Inc., Raleigh, North Carolina, USA</addr-line>
</aff>
<aff id="aff2"><label>b</label>
<addr-line>Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA</addr-line>
</aff>
<aff id="aff3"><label>c</label>
<addr-line>Institutional Office of Regulated Nonclinical Studies, University of Texas Medical Branch, Galveston, Texas, USA</addr-line>
</aff>
<aff id="aff4"><label>d</label>
<addr-line>Department of Pathology, University of Texas Medical Branch, Galveston, Texas, USA</addr-line>
</aff>
<aff id="aff5"><label>e</label>
<addr-line>Sealy Institute for Vaccine Sciences, University of Texas Medical Branch, Galveston, Texas, USA</addr-line>
</aff>
<aff id="aff6"><label>f</label>
<addr-line>Bioscience Division, SRI International, Menlo Park, California, USA</addr-line>
</aff>
</contrib-group>
<author-notes><corresp id="cor1">Address correspondence to Peter B. Madrid, <email>peter.madrid@sri.com</email>
, or Sean Ekins, <email>sean@collaborationspharma.com</email>
.</corresp>
<fn fn-type="other"><p><bold>Citation</bold>
 Lane TR, Comer JE, Freiberg AN, Madrid PB, Ekins S. 2019. Repurposing quinacrine against Ebola virus infection <italic>in vivo</italic>
. Antimicrob Agents Chemother 63:e01142-19. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1128/AAC.01142-19">https://doi.org/10.1128/AAC.01142-19</ext-link>
.</p>
</fn>
</author-notes>
<pub-date pub-type="epreprint"><day>15</day>
<month>7</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub"><day>23</day>
<month>8</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="collection"><month>9</month>
<year>2019</year>
</pub-date>
<volume>63</volume>
<issue>9</issue>
<elocation-id>e01142-19</elocation-id>
<history><date date-type="received"><day>3</day>
<month>6</month>
<year>2019</year>
</date>
<date date-type="rev-request"><day>26</day>
<month>6</month>
<year>2019</year>
</date>
<date date-type="accepted"><day>2</day>
<month>7</month>
<year>2019</year>
</date>
</history>
<permissions><copyright-statement>Copyright © 2019 American Society for Microbiology.</copyright-statement>
<copyright-year>2019</copyright-year>
<copyright-holder>American Society for Microbiology</copyright-holder>
<license license-type="asm" xlink:href="https://doi.org/10.1128/ASMCopyrightv2"><license-p><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1128/ASMCopyrightv2">All Rights Reserved</ext-link>
.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="AAC.01142-19.pdf"></self-uri>
<abstract abstract-type="precis"><p>Quinacrine hydrochloride is a small-molecule, orally bioavailable drug that has been used clinically as an antimalarial and for many other applications. A machine learning model trained on Ebola virus (EBOV) screening data identified quinacrine as a potent (nanomolar) <italic>in vitro</italic>
 inhibitor.</p>
</abstract>
<abstract><title>ABSTRACT</title>
<p>Quinacrine hydrochloride is a small-molecule, orally bioavailable drug that has been used clinically as an antimalarial and for many other applications. A machine learning model trained on Ebola virus (EBOV) screening data identified quinacrine as a potent (nanomolar) <italic>in vitro</italic>
 inhibitor. In the current study, quinacrine 25 mg/kg was shown to protect 70% of mice (statistically significant) from a lethal challenge with mouse-adapted EBOV with once-daily intraperitoneal dosing for 8 days.</p>
</abstract>
<kwd-group><title>KEYWORDS</title>
<kwd>Ebola virus</kwd>
<kwd>Ebola virus disease</kwd>
<kwd>antiviral</kwd>
<kwd>quinacrine</kwd>
</kwd-group>
<funding-group><award-group id="award1"><funding-source><institution-wrap><institution>HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID)</institution>
<institution-id>https://doi.org/10.13039/100000060</institution-id>
</institution-wrap>
</funding-source>
<award-id>HHSN272201000040I</award-id>
<principal-award-recipient><name><surname>Madrid</surname>
<given-names>Peter B.</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award2"><funding-source><institution-wrap><institution>HHS | NIH | National Center for Advancing Translational Sciences (NCATS)</institution>
<institution-id>https://doi.org/10.13039/100006108</institution-id>
</institution-wrap>
</funding-source>
<award-id>R21TR001718</award-id>
<principal-award-recipient><name><surname>Ekins</surname>
<given-names>Sean</given-names>
</name>
</principal-award-recipient>
</award-group>
</funding-group>
<counts><count count="1" count-type="supplementary-material"></count>
<fig-count count="2"></fig-count>
<table-count count="1"></table-count>
<equation-count count="0"></equation-count>
<ref-count count="31"></ref-count>
<page-count count="8"></page-count>
<word-count count="5105"></word-count>
</counts>
<custom-meta-group><custom-meta><meta-name>cover-date</meta-name>
<meta-value>September 2019</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
</pmc>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Pmc/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000263 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 000263 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    ChloroquineV1
   |flux=    Pmc
   |étape=   Corpus
   |type=    RBID
   |clé=     PMC:6709481
   |texte=   Repurposing Quinacrine against Ebola Virus Infection In Vivo
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/RBID.i   -Sk "pubmed:31307979" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a ChloroquineV1

This area was generated with Dilib version V0.6.33.
Data generation: Wed Mar 25 22:43:59 2020. Site generation: Sun Jan 31 12:44:45 2021

	Serveur d'exploration Chloroquine
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration Chloroquine

Repurposing Quinacrine against Ebola Virus Infection In Vivo

Repurposing Quinacrine against Ebola Virus Infection In Vivo

Source :

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki